New Brunswick, N.J.-based Johnson & Johnson (J&J) executives expressed enthusiasm with Q4 and full-year 2018 results Tuesday, even as pricing pressure continued to affect orthopedics. While the company reported its 2019 full-year guidance for sales of $80.4 billion to $81.2 billion, Cowen analyst Joshua Jennings noted that the consensus estimate had been $82.57 billion. Still, he saw progress with medical devices, along with the company's other business segments. "These sales trends, along with what we view as conservative 2019 guidance ranges, should be enough to support shares," he wrote. Read More
